急性肺血管扩张试验在先天性心脏病相关性肺动脉高压中的意义The significance of acute pulmonary vasodilator testing in pulmonary hypertension associated with congenital heart disease
刘洋,沈群山,张刚成,尚小珂,王利军,卢蓉,余莹,陈谦
摘要(Abstract):
目的探讨急性肺血管扩张试验(acute pulmonary vasodilator testing,AVT)在先天性心脏病相关性肺动脉高压(CHD-PAH)中的作用。方法对2008年3月至2014年4月在武汉亚洲心脏病医院行右心导管及AVT检查的479例患者的临床资料进行回顾性分析,其中男105例,女374例。所有患者均采用吸入伊洛前列素行AVT检查,分别观察AVT检查的阳性率。并采集CHD-PAH患者行AVT检查前后的平均肺动脉压力(mP AP)、全肺血管阻力(TPR)、肺小动脉楔压(PCWP)、心输出量(CO)、肺循环血量/体循环血量(Qp/Qs)、肺循环阻力/体循环阻力(Rp/Rs)的变化。结果 479例CHD-PAH患者行AVT检查阳性患者为0例。479例CHD-PAH患者行AVT检查后mP AP由(69.2±15.7)mmH g(1 mmH g=0.133 kP a)降至(58.6±10.8)mmH g,TPR由(21.6±13.2)wood降至(18.8±6.8)wood,Qp/Qs由(1.6±1.3)升至(1.8±1.2),Rp/Rs由(0.9±0.2)降至(0.7±0.2)(P<0.01),CO及PCWP差异无统计学意义。479例CHD-PAH患者中达到手术标准的仅有34例患者,其中33例患者实施外科手术,随访6个月预后良好。结论 CHD-PAH患者行AVT检查的意义并不在于选择钙拮抗剂进行治疗,而是在于评价CHD-PAH患者是否有外科手术的适应证。
关键词(KeyWords): 先天性心脏病;高血压;肺性;急性肺血管扩张试验
基金项目(Foundation): 国家十二五科技支撑项目(2011BAI11B15);; 湖北省卫生厅科研项目(JX6B90)
作者(Author): 刘洋,沈群山,张刚成,尚小珂,王利军,卢蓉,余莹,陈谦
参考文献(References):
- [1]尚小珂,张刚成,柳梅.单纯继发孔房间隔缺损导管介人封堵与外科微创封堵的比较.中国介入心脏病学杂志,2012,20:20-23.
- [2]中华医学会心血管分会.心血管疾病防治指南共识2012.北京:人民卫生出版社2012:120.
- [3]中华医学会小儿外科学分会胸心外科学组.小儿先天性心脏病相关性肺高压诊断和治疗(专家共识).中华小儿外科杂志,2011,32:306-318.
- [4]刘海菊,顾虹.急性肺血管药物扩张试验在评价先天性心脏病合并重度肺动脉高压中的应用进展.心肺血管病杂志,2011,30:344-347.
- [5]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.肺动脉高压筛查诊断与治疗专家共识.中华心血管病杂志,2007,35:979-987.
- [6]MeL aushlin VV,Archer SL,Badesch DB,et al.ACCF/AHA 2009expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians;American Thoracic Society,Inc.;and the Pulmonary Hypertension Association.J Am Coll Cardiol,2009,53:1573-1619.
- [7]GalièN,Hoeper MM,Humbert M,et al.Guidelines for the diagnosis and treatment of pulmonary hypertension:the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC)and the European Respiratory Society(ERS),endorsed by the International Society of Heart and Lung Transplantation(ISHLT).Eur Heart J,2009,30:2493-2537.
- [8]朱鲜阳,张瑞珍.急性肺血管反应试验在肺动脉高压中的作用.中国医师进修杂志,2009,32:1-4.
- [9]傅立军,周爱卿,郭颖等.儿童特发性肺动脉高压的急性肺血管扩张试验.中华儿科杂志,2011,49:886-889.
- [10]Sitbon O,Humbert M,Jas X,et al.Long-Term response to calcium channel blockers in Idiopathic pulmonary arterial hypertension.Circulation,2005,111:3105-3111.
- [11]Badesch DB,Abman SH,Simonneau G,et al.Medical therapy for pulmonary arterial hypertension:updated ACCP evidencebased clinical practice guidelines.Chest,2007,131:1917-1928.
- [12]张宏达,邱梅红,荆志成.急性肺血管扩张试验筛查在肺动脉高压中的应用.世界临床药物,2013,34:271-275.
- [13]荆志成.2010年中国肺高血压诊治指南.中国医学前沿杂志(电子版)2011,3:62-81.
- [14]Tonelli AR,Alnuaimat H,Mubarak K.Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension.Respir Med,2010,104:481-496.
- [15]Jing ZC,Jiang X,Han ZY.Iloprost for pulmonary vasodilator testing inidiopathic pulmonary arterial hypertension.Eur Respir J,2009,33:1354-1360.
- [16]Sitbon O,Brenot F,Denjean A,et al.Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension.A dose-response study and comparison with prostacyclin.Am J Respir Crit Care Med,1995,151:384-389.
- [17]Montani D,Savale L,Natali D,et al.Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension.Eur Heart J,2010,31:1898-1907.
- [18]Tonelli AR,Alnuaimat H,Mubarak K.Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension.RespirM ed,2010,104:481-496.
- [19]Barst RJ,Agnoletti G,Fraisse A,et al.Vasodilator testing with nitric oxide and/or oxygen in pediatric pulmonary hypertension.Pediatr Cardiol,2010,31:598-606.
- [20]Balzer DT,Kort HW,Day RW,et al.Inhaled Nitric Oxide as a Preoperative Test(INOP Test I):the INOP Test Study Group.Circulation,2002,106[suppl I]:176-181.
- [21]顾虹,李强强,张陈,等.吸入伊洛前列素行急性肺血管扩张试验在先天性心脏病合并重度肺动脉高压术前评估中的作用.中华外科杂志,2010,48:727-730.
- [22]张刚成,沈群山,尚小珂,等.经皮导管介人封堵与外科微创封堵治疗室间隔缺损的对比研究.中国介入心脏病学杂志,2013,21:17-20.